

COSMIC Actionability v9 - Release Notes

COSMIC Actionability is a vital tool for anyone working in precision oncology. Our expertly curated database details the availability and development of drugs targeting somatic mutations in cancer. We integrate data from case studies, clinical trials, and regulatory bodies to represent a full picture of the current precision oncology pipeline.

Actionability has three core units: mutation, disease and drug. By capturing relations between these units, we identify existing and upcoming drugs that target specific genetic variants in different cancer types.

COSMIC's trusted expert-curation process is embedded within Actionability, but it exists as a standalone product. Releases of Actionability occur more frequently than COSMIC to better reflect the rapid pace of global precision oncology. Actionability is a cutting edge 'living-tool' and the data is intended to be as up to date as possible.

Actionability downloads are free for Academic Non-Commercial Use* via COSMIC or available to purchase and download from QIAGEN. A taster file of EGFR data can be accessed [here](#)

If you'd like to know more about the curation process behind Actionability, read our interview with [Principal Curator, Steve Jupe](#)

**Please see full terms and conditions of commercial and non-commercial use on our [licensing pages](#).*

Updates

COSMIC Actionability v9 includes **5** additional fully-curated genes:
ESR1, CCND1, CCND2, CCND3 and RB1

This means we have a total of **99** fully curated genes:

ABL1, AKT1, AKT2, AKT3, ALK, AR, ASXL1, ATM, ATR, BCL2, BCR, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CD274 (PD-L1), CD33, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK2, CTNNB1, DDR2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ESR1, ETV6, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GNA11, GNAS, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KMT2A, KRAS, MAP2K1 (MEK1), MAP2K2, MDM2, MDM4, MET, MLH, MPL, MSH2, MSH6, MTOR, MYD88, NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PMS2, PTCH1, PTEN, PTPN11, RAF1, RB1, RET, ROS1, RUNX1, SF3B1, SMAD4, SMO, STK11, SYK, TERT, TET2, TP53, TSC1, VHL, WT1

To view the full list of curated genes visit the [About](#) page on the Actionability website. All previously-recorded clinical trials have been checked for new or updated results.

Actionability statistics - v9

99	Genes fully curated (+5)
372	Genes included (+15)
1835	Drugs (+100)
4796	Treatment combinations (+566)
4610	Trials with results (+633)
5746	Trials with no results (+315)
10356	Total trials (+948)
7364	Evidence from trial databases (+643)
3177	Evidence from PubMed & others (+322)
10541	Total Sources (+965)
154	Point Mutations (0)
876	Total Variants (+72)

Accessing Actionability - T&Cs

Actionability v7 and all subsequent releases will be freely available for non-commercial use. Please see our terms for clarification on commercial/non-commercial use.

Please make sure you read and understand whether you count as commercial via our [licensing page](#)

If you are using COSMIC Actionability for non-commercial purposes, you can register for an account and download the data directly from [COSMIC](#) (<https://cancer.sanger.ac.uk/cosmic/download>)

To access COSMIC Actionability for commercial use, please contact our Sales Partner [QIAGEN](#)